Mutant Huntingtin Downregulates Myelin Regulatory Factor-Mediated Myelin Gene Expression and Affects Mature Oligodendrocytes

[1]  S. Dunnett,et al.  Mouse Models of Huntington's Disease. , 2015, Current topics in behavioral neurosciences.

[2]  O. Phillips,et al.  Deep White Matter in Huntington's Disease , 2014, PloS one.

[3]  William D. Richardson,et al.  Motor skill learning requires active central myelination , 2014, Science.

[4]  S. Petratos,et al.  Axonal degeneration in multiple sclerosis: can we predict and prevent permanent disability? , 2014, Acta neuropathologica communications.

[5]  A. L. Goldin,et al.  Role of the hippocampus in Nav1.6 (Scn8a) mediated seizure resistance , 2014, Neurobiology of Disease.

[6]  O. Phillips,et al.  MRI measures of corpus callosum iron and myelin in early Huntington's disease , 2014, Human brain mapping.

[7]  C. Messier,et al.  From precursors to myelinating oligodendrocytes: Contribution of intrinsic and extrinsic factors to white matter plasticity in the adult brain , 2014, Neuroscience.

[8]  Jane S. Paulsen,et al.  Huntington disease: natural history, biomarkers and prospects for therapeutics , 2014, Nature Reviews Neurology.

[9]  F. Gage,et al.  Mutant Huntingtin Promotes Autonomous Microglia Activation via Myeloid Lineage-determining Factors Fold Difference from the Mean , 2022 .

[10]  Yan Ao,et al.  Astrocyte Kir4.1 ion channel deficits contribute to neuronal dysfunction in Huntington's disease model mice , 2014, Nature Neuroscience.

[11]  M. Wegner,et al.  The Transcription Factors Sox10 and Myrf Define an Essential Regulatory Network Module in Differentiating Oligodendrocytes , 2013, PLoS genetics.

[12]  S. Yu,et al.  Synaptic mutant huntingtin inhibits synapsin-1 phosphorylation and causes neurological symptoms , 2013, The Journal of cell biology.

[13]  C. Lelliott,et al.  Peroxisome proliferator‐activated receptor gamma‐coactivator‐1 alpha coordinates sphingolipid metabolism, lipid raft composition and myelin protein synthesis , 2013, The European journal of neuroscience.

[14]  X. W. Yang,et al.  Genetic manipulations of mutant huntingtin in mice: new insights into Huntington's disease pathogenesis , 2013, The FEBS journal.

[15]  B. Barres,et al.  MYRF Is a Membrane-Associated Transcription Factor That Autoproteolytically Cleaves to Directly Activate Myelin Genes , 2013, PLoS biology.

[16]  E. Marcotte,et al.  A Bacteriophage Tailspike Domain Promotes Self-Cleavage of a Human Membrane-Bound Transcription Factor, the Myelin Regulatory Factor MYRF , 2013, PLoS biology.

[17]  Yue Feng,et al.  Oligodendroglia and neurotrophic factors in neurodegeneration , 2013, Neuroscience Bulletin.

[18]  Y. Li,et al.  Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis , 2013, Nature Neuroscience.

[19]  W. Richardson,et al.  Oligodendrocyte dysfunction in the pathogenesis of amyotrophic lateral sclerosis. , 2013, Brain : a journal of neurology.

[20]  Hongye Liu,et al.  Separated at birth? The functional and molecular divergence of OLIG1 and OLIG2 , 2012, Nature Reviews Neuroscience.

[21]  A W Toga,et al.  Multimodal MRI analysis of the corpus callosum reveals white matter differences in presymptomatic and early Huntington's disease. , 2012, Cerebral cortex.

[22]  T. Kilpatrick,et al.  Myelin Gene Regulatory Factor Is Required for Maintenance of Myelin and Mature Oligodendrocyte Identity in the Adult CNS , 2012, The Journal of Neuroscience.

[23]  Shihua Li,et al.  Influence of species differences on the neuropathology of transgenic Huntington's disease animal models. , 2012, Journal of genetics and genomics = Yi chuan xue bao.

[24]  Pierre J. Magistretti,et al.  Oligodendroglia metabolically support axons and contribute to neurodegeneration , 2012, Nature.

[25]  Jens Frahm,et al.  Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity , 2012, Nature.

[26]  E. Cattaneo,et al.  Emerging roles for cholesterol in Huntington's disease , 2011, Trends in Neurosciences.

[27]  Wenzhen Duan,et al.  Peroxisome-Proliferator-Activated Receptor Gamma Coactivator 1 α Contributes to Dysmyelination in Experimental Models of Huntington's Disease , 2011, The Journal of Neuroscience.

[28]  R. Kothary,et al.  The Proteolipid Protein Promoter Drives Expression outside of the Oligodendrocyte Lineage during Embryonic and Early Postnatal Development , 2011, PloS one.

[29]  Anusha Sritharan,et al.  Diffusion Tensor Imaging in Huntington’s disease reveals distinct patterns of white matter degeneration associated with motor and cognitive deficits , 2011, Brain Imaging and Behavior.

[30]  G. Bates,et al.  The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease. , 2011, The Journal of clinical investigation.

[31]  K. Nave,et al.  Cholesterol: A Novel Regulatory Role in Myelin Formation , 2011, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[32]  C. Ross,et al.  Huntington's disease: from molecular pathogenesis to clinical treatment , 2011, The Lancet Neurology.

[33]  B. Emery.  Regulation of Oligodendrocyte Differentiation and Myelination , 2010, Science.

[34]  Jeffrey H Kordower,et al.  Differential vulnerability of neurons in Huntington’s disease: the role of cell type‐specific features , 2010, Journal of neurochemistry.

[35]  Chuan-en Wang,et al.  Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms , 2009, Proceedings of the National Academy of Sciences.

[36]  K. Ligon,et al.  Myelin Gene Regulatory Factor Is a Critical Transcriptional Regulator Required for CNS Myelination , 2009, Cell.

[37]  N. Kessaris,et al.  PDGFRA/NG2 glia generate myelinating oligodendrocytes and piriform projection neurons in adult mice , 2008, Nature Neuroscience.

[38]  Robin J. M. Franklin,et al.  Remyelination in the CNS: from biology to therapy , 2008, Nature Reviews Neuroscience.

[39]  R. Albin,et al.  Rodent genetic models of Huntington disease , 2008, Neurobiology of Disease.

[40]  M. Hayden,et al.  Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington's disease. , 2008, Human molecular genetics.

[41]  A. Jennifer Morton,et al.  Atrophy and degeneration in sciatic nerve of presymptomatic mice carrying the Huntington's disease mutation , 2008, Brain Research.

[42]  Y. Xing,et al.  A Transcriptome Database for Astrocytes, Neurons, and Oligodendrocytes: A New Resource for Understanding Brain Development and Function , 2008, The Journal of Neuroscience.

[43]  Jim Mintz,et al.  Myelin Breakdown and Iron Changes in Huntington’s Disease: Pathogenesis and Treatment Implications , 2007, Neurochemical Research.

[44]  Michelle K. Lupton,et al.  The Hdh Q150/Q150 knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes , 2007, Brain Research Bulletin.

[45]  D. Townsend,et al.  “Skittish” Abca2 Knockout Mice Display Tremor, Hyperactivity, and Abnormal Myelin Ultrastructure in the Central Nervous System , 2006, Molecular and Cellular Biology.

[46]  K. Ligon,et al.  Olig gene function in CNS development and disease , 2006, Glia.

[47]  Ji-Yeon Shin,et al.  Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity , 2005, The Journal of cell biology.

[48]  B. Harper.  Huntington Disease , 2005, Journal of the Royal Society of Medicine.

[49]  I. Módy,et al.  Pathological Cell-Cell Interactions Elicited by a Neuropathogenic Form of Mutant Huntingtin Contribute to Cortical Pathogenesis in HD Mice , 2005, Neuron.

[50]  Jane S. Paulsen,et al.  In vivo evidence of cerebellar atrophy and cerebral white matter loss in Huntington disease , 2004, Neurology.

[51]  Xiao-Jiang Li,et al.  Huntingtin-protein interactions and the pathogenesis of Huntington's disease. , 2004, Trends in genetics : TIG.

[52]  Wilhelm Gaus,et al.  Evidence for more widespread cerebral pathology in early HD: An MRI-based morphometric analysis , 2004, Neurology.

[53]  Erich E Wanker,et al.  The hunt for huntingtin function: interaction partners tell many different stories. , 2003, Trends in biochemical sciences.

[54]  G. Kidd,et al.  Proteolipid Promoter Activity Distinguishes Two Populations of NG2-Positive Cells throughout Neonatal Cortical Development , 2002, The Journal of Neuroscience.

[55]  H Li,et al.  Huntingtin Aggregate-Associated Axonal Degeneration is an Early Pathological Event in Huntington's Disease Mice , 2001, The Journal of Neuroscience.

[56]  Moses Rodriguez,et al.  Quantitative ultrastructural analysis of a single spinal cord demyelinated lesion predicts total lesion load, axonal loss, and neurological dysfunction in a murine model of multiple sclerosis. , 2000, The American journal of pathology.

[57]  F. Kirchhoff,et al.  Purification and analysis of in vivo-differentiated oligodendrocytes expressing the green fluorescent protein. , 2000, Developmental biology.

[58]  Alan C. Evans,et al.  Structural maturation of neural pathways in children and adolescents: in vivo study. , 1999, Science.

[59]  B. Scheithauer,et al.  Ultrastructure of multiple sclerosis. , 1994, Ultrastructural pathology.

[60]  K. Abromeit.  Music Received , 2023, Notes.